CONFRONTING PICTURE OF GROWING WOMEN’S HEALTH CRISIS IN UTERINE CANCERS. ANZGOG State of the Nation report highlights inequities in uterine cancer outcomes across Australia
With
Associate Professor Yoland Antill, Director and Deputy Chair, Australia New Zealand Gynaecological Oncology Group (ANZGOG)
SEGMENT
Filmed in Melbourne | December 2025
Uterine cancers have become Australia’s fastest-growing women’s cancer, with incidence doubling over the past 25 years and projected to continue to surge. Without immediate action, more than 44,000 women are expected to be diagnosed by 2035, and 8,900 will lose their lives to the disease.
Released November 2025, Australia’s first State of the Nation: Uterine Cancers in Australia 2025 report by the Australia New Zealand Gynaecological Oncology Group (ANZGOG), reveals a confronting picture of a growing women’s health crisis that has gone largely unseen and one that now requires immediate, coordinated national action.
Once considered a cancer that primarily affected older women, the report highlights an alarming new trend: incidence is now rising fastest among women aged 25 to 44, with cases in this age group expected to increase by around 60 per cent alone, over the next decade.
Despite its growing impact, uterine cancer remains largely invisible in Australia’s cancer conversation. The limited research available notes, 94 per cent of women are unaware of what uterine or endometrial cancers are yet increased awareness of the disease and risk factors could prevent up to 60 per cent of future diagnoses. Research investment for uterine cancers lags far behind other cancers.
In addition, support and psychosocial care for women living with uterine cancers are inconsistent, and currently there is no dedicated national advocacy organisation. Many women face pain, fatigue, anxiety and long-term side effects alone.
State of the Nation report sets out a national plan to reverse the rise in uterine cancers and transform outcomes for Australian women
The report identifies five urgent priorities: halve incidence, eliminate inequities, ensure access to precision care, support every woman to live well, and invest in research and data. Achieving these goals will require united action from government, researchers, clinicians, industry and the community to deliver the innovation, equity and support Australian women deserve.
Source: Adapted from ANZGOG media release November 2025
Report: ANZGOG State of the Nation Report into Uterine Cancers can be read here https://www.anzgog.org.au/sotn-uterine-cancer, prepared by Insight Economics
-
Understanding extracellular vesicles in cancer therapy research
Joy Wolfram is an Associate Professor at the Australian Institute for Bioengineering and Nanotechnology and the School of Chemical Engineering at the University of Queensland in Australia. Originally from Finland, she earned both her bachelor’s and master’s degrees in biology before transitioning to engineering with a PhD in nanotechnology completed in China. Wolfram has over a decade of experience working in hospitals in the United States before joining the University of Queensland.
Her research focuses on extracellular vesicles, which are crucial for cell communication both locally within tissues and over longer distances between organs. Her lab studies the roles of these vesicles in both health and disease, particularly in cancer. They investigate the harmful messages released by cancer cells that aid in tumour growth, specifically in breast cancer, while also exploring how to harness beneficial extracellular vesicles from healthy individuals as potential therapeutics.
-
Continuing education program leads to better conversations
Medicines Australia’s Continuing Education Program (CEP) is designed to educate medical representatives to a recognised industry standard. Dr Tristan Ling, CEP Academic Lead and Project Manager at the College of Health and Medicine, University of Tasmania talks about the 900 students that come through the program each year.
The CEP is primarily directed at medical representatives working within the prescription medicines industry, but is also recommended to people who may not be currently employed within the industry but would like to pursue a career as a medical representative. It is also available to personnel working for organisations interacting with the pharmaceutical industry.
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
